Is Ozempic for Weight Loss or Diabetes?

Last reviewed: June 26, 2026

Last updated: June 26, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, the active ingredient in Ozempic and Wegovy, is FDA-approved for treating both type 2 diabetes and chronic weight management in adults with obesity. The same medication addresses two different health conditions because it works through a single biological pathway—the glucagon-like peptide-1 (GLP-1) receptor—that influences blood sugar control, appetite regulation, and metabolic rate.

How Semaglutide Works for Diabetes and Weight Loss

Semaglutide activates GLP-1 receptors located throughout the brain, pancreas, and digestive tract. In the pancreas, it stimulates insulin release when blood glucose rises, helping lower blood sugar in people with type 2 diabetes. In the brain, it signals satiety centers that reduce hunger and increase feelings of fullness—the mechanism behind weight loss.

Clinical trials show semaglutide reduces hemoglobin A1C (a marker of long-term blood sugar control) by up to 2 percentage points in diabetic patients. The same trials demonstrate 10-22% body weight reduction in individuals without diabetes who received higher doses. This dual benefit occurs because one medication targets multiple organs and systems that both regulate glucose and control appetite.

Key Differences Between Ozempic and Wegovy Dosing

Ozempic is prescribed for type 2 diabetes at starting doses of 0.25 mg weekly, typically titrated to 1 mg weekly. Wegovy, the weight-loss version, follows a similar titration schedule but reaches 2.4 mg weekly for obesity treatment. Both contain identical semaglutide, but marketing and indication differ based on the condition being treated and the target dose range.

PlexusDx provides compounded semaglutide injection with personalized dosing protocols based on your metabolic profile and health goals. Your dose may need to go up as your body adapts, but your price stays flat at $149 monthly across all dose levels—ensuring affordability regardless of where your treatment progresses.

Semaglutide Effectiveness Data for Weight Loss

The STEP trials (Semaglutide Treatment Effect in People with obesity) enrolled over 4,500 participants and measured weight loss over 68 weeks. Participants receiving 2.4 mg weekly semaglutide lost an average of 94 pounds, compared to 11 pounds in the placebo group. This represents approximately 15% of baseline body weight—a clinically significant reduction that improves metabolic health, mobility, and disease risk.

For people with type 2 diabetes, the SUSTAIN trials showed semaglutide reduced body weight by 3-6 kg at lower doses (0.5-1.0 mg weekly) while simultaneously improving blood sugar control. Many diabetes patients experience dual benefits: better glucose management and modest weight loss, which further improves insulin sensitivity and reduces medication burden.

Personalized Treatment: The PlexusDx Precision Peptide Genetic Test

Not everyone responds identically to semaglutide. Your genetic profile influences how efficiently your body uses GLP-1 signaling pathways and how strongly you experience appetite suppression. The PlexusDx Precision Peptide Genetic Test ($298) analyzes 49 peptides across 14 metabolic pathways, including key variants in GIPR gene (rs1800437), the FTO gene (rs9939609), and the MC4R gene (rs17782313).

These genetic insights reveal whether you have high, moderate, or low predicted responsiveness to GLP-1 therapy and help inform optimal dosing strategies. Patients with certain genetic variants may benefit from faster titration or combination peptide therapies (such as tirzepatide, which also activates the GIP receptor). PlexusDx uses your test results to refine your personalized treatment plan within weeks of starting therapy.

Cost and Access: No Insurance Required

PlexusDx compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan) and is available in all 50 states without insurance, membership fees, or prior authorization delays. The medication is prepared by licensed 503A compounding pharmacies and is HSA/FSA eligible, allowing you to use tax-advantaged health savings accounts to pay. Rapid shipping and discreet packaging ensure privacy and convenience.

If you prefer oral semaglutide, PlexusDx offers that option at $289/mo (or $249/mo on the 6-month plan). Both injection and oral forms deliver the same active ingredient with identical clinical efficacy—the choice depends on your comfort with self-injection and personal preference. Treatment begins within days of your initial consultation, not weeks.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is semaglutide only for diabetes or weight loss?

Semaglutide treats both conditions through the same biological mechanism. When prescribed for type 2 diabetes (Ozempic), it improves blood sugar control and often produces weight loss as a secondary benefit. When prescribed for obesity (Wegovy), it reduces appetite and body weight while also improving glucose metabolism. PlexusDx compounded semaglutide injection ($189/mo) serves patients with either condition or both.

How much weight do people typically lose on semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Can I start semaglutide without a diabetes diagnosis?

Yes. Semaglutide is FDA-approved for weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related health conditions. You do not need diabetes to qualify. PlexusDx serves all 50 states and evaluates each patient individually during your consultation to ensure semaglutide aligns with your health goals.

Does the price change if my dose increases?

No. PlexusDx compounded semaglutide injection maintains a flat price of $189 per month regardless of dose level. Your dose may need to go up as your body adjusts and tolerates higher amounts—but your price won't. This transparent pricing model removes cost barriers to dose optimization.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Is compounded semaglutide as safe as brand-name Ozempic or Wegovy?

PlexusDx compounded semaglutide is prepared by licensed 503A compounding pharmacies under strict FDA oversight. Compounded medications meet the same purity, sterility, and potency standards as brand-name equivalents. The active ingredient is identical; the difference is cost and accessibility. Always discuss your medical history with your PlexusDx provider before starting any GLP-1 therapy.

Related Reading

• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic
• Ozempic Weight Loss Before And After Pictures

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.